Results 291 to 300 of about 225,115 (385)

A phase IIb single-center study to assess the efficacy of apremilast for the treatment of nummular eczema. [PDF]

J Dtsch Dermatol Ges
Böhner A, Seiringer P, Kleeberger V, Rogner D, Oesterlin C, Biedermann T, Eyerich K, Lauffer F.   +7 more
europepmc   +1 more source

AMMONIA PLUS ANOTHER FACTOR ARE NECESSARY FOR DIFFERENTIATION IN SUBMERGED CLUMPS OF DICTYOSTELIUM [PDF]

, 1979
David, Charles N., Sternfeld, John
core  

Systemic treatment of immune checkpoint inhibitor‐induced psoriasis: Inference‐based guidance

Journal of the European Academy of Dermatology and Venereology, EarlyView.
When managing psoriasis, induced or exacerbated by ICI therapy for cancer, there are concerns regarding immunosuppression from systemic agents for the treatment of psoriasis and the potential impact on ICI efficacy. No direct, high‐level evidence exists to address these concerns.
Kim A. Papp, Luis Puig, Jennifer Beecker, Vinod Chandran, Joël Claveau, Javier Cortés, Jan Dutz, Noah I. Hornick, Rosalyn A. Juergens, Barbara Melosky, Anisha B. Patel, Maxwell B. Sauder, Sandeep Sehdev, Vincent Sibaud, Stephanie L. Snow   +14 more
wiley   +1 more source

Assessment of Risk Factors for Vasoplegic Syndrome in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass. [PDF]

Cureus
Meyer KA, Brink HL, Brannan SC, Lundgren SW, Lyden ER, Behlers QB.   +5 more
europepmc   +1 more source

Efficacy and safety of ME3183, an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
We assessed four different doses of ME3183, a novel phosphodiesterase 4 inhibitor, and placebo in 132 patients with moderate to severe plaque psoriasis. At Week 16, more patients receiving ME3183 achieved ≥75% reduction in baseline Psoriasis Area and Severity Index scores than those receiving placebo, with no new safety concerns.
Kim A. Papp, April W. Armstrong, Tomokazu Koresawa, Kazunari Otake, Masayuki Hirata, Akiko Kano   +5 more
wiley   +1 more source

Prostacyclin Therapy as Adjunctive Treatment for Pulmonary Hypertension in Pediatric Heart Transplantation: A Case Report. [PDF]

Pediatr Transplant
Konduri A, Sonnen AJ, Lim HM, Schumacher KR, Peng DM, Sood V, Olive MK, McCormick AD.   +7 more
europepmc   +1 more source

Targeted Alkaline Phosphatase Therapy Enhances Alveolar Bone Healing in X‐Linked Hypophosphatemia in Mice

Journal of Periodontal Research, EarlyView.
Effects of exogenous tissue‐nonspecific alkaline phosphatase (TNAP) were analyzed in the Hyp mouse model of X‐linked hypophosphatemia (XLH). Maxillary first molars were extracted from wild‐type (WT) and Hyp mice at 6 weeks, and collagen gel ± TNAP was placed in sockets. In one group of Hyp mice, submucosal injections of TNAP or saline were delivered at
Aonjittra Phanrungsuwan, Bella Donnelly, José Luis Millán, Brian L. Foster   +3 more
wiley   +1 more source

Isolation and characterization of PDE-I and II, the inhibitors of cyclic adenosine-3',5'-monophosphate phosphodiesterase.

, 1978
Yûji Enomoto, Yoshio Furutani, HIROSHI NAGANAWA, MASA HAMADA, TOMIO TAKEUCHI, HAMAO UMEZAWA   +5 more
openalex   +2 more sources

The long‐term outcome and changes in tricuspid regurgitation pressure gradient in dogs diagnosed with pulmonary hypertension and Angiostrongylus vasorum infestation

Journal of Small Animal Practice, EarlyView.
Objectives Angiostrongylus vasorum (AV) is a metastrongylid parasite that has been associated with pulmonary hypertension (PH) in dogs. The objectives of the study were to describe the clinical presentation of dogs with AV and PH, document changes in tricuspid regurgitation maximum pressure gradient (TR Max PG) in subsequent months and years, record ...
R. Turner, D. Connolly, D. Brodbelt, S. Cortellini   +3 more
wiley   +1 more source

ATP8B1 Deficiency Causes Phosphodiesterase 4-Mediated Glucagon Resistance and Impaired Gluconeogenesis in Mouse and Human Liver. [PDF]

Liver Int
Chang JC, Panhuis WIH, Hsu SH, Duijst S, Ho-Mok KS, van der Heiden JF, Ying Z, Erdmann JI, Vogel GF, Junge N, Hartleben B, Koelink PJ, van Dijk SG, Peng WC, Verhoeven AJ, Oude Elferink RPJ, Chen HL, van de Graaf SFJ, Paulusma CC.   +18 more
europepmc   +1 more source